Publications

onc201

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

J Neurooncol. 2019 PMID: 31456142

Chi AS, Tarapore RS, Hall MD, et al.

imipridones

Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules

ACR Annual Meeting 2019

Prabhu VV, Kawakibi AR, Madhukar NS, et al.

onc201

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

J Immunother Cancer. 2019 PMID: 31118108

Stein MN, Malhotra J, Tarapore RS, et al.

imipridones

Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality

Cancer Cell 2019 PMID: 31056398

Ishizawa J, Zarabi SF, Davis RE, et al.

dstat

A randomized phase II trial of CX-01 with standard therapy in elderly patients with Acute Myeloid Leukemia (AML)

Journal of Clinical Oncology 2019

Kovacsovics T, Levy MY, Cook RJ, et al.

onc212

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.

Leukemia. 2019 PMID: 31127149

Nii T, Prabhu VV, Ruvolo V, et al.

onc201

Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism

Clin Cancer Res. 2019 PMID: 30559168

Prabhu VV, Madhukar NS, Gilvary C, et al.

onc201

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

J Clin Invest. 2018 PMID: 29533922

Wagner J, Kline CL, Zhou L, et al.

dstat

Combination of the low anticoagulant heparin CX‑01 with chemotherapy for the treatment of acute myeloid leukemia

Blood Adv. 2018

Kovacsovics TJ, Mims A, Salama ME, et al.

dstat

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia

Blood Advances 2018

Tkaczynski E, Arulselvan A, Tkaczynski J, et al.